Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reolysin with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02514382Phase 1Completed
- Sponsor
- University of Southern California
- Start
- Aug 2015
- Primary completion
- Apr 2022
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelareorep in multiple myeloma (MM), sponsored by University of Southern California. Primary endpoint: Incidence of adverse events assessed by CTCAE version 4.03. Started Aug 2015; status: completed.
02
Drugs
pelareorep
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02514382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514382.